AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.AbbVie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

Media:

Gabby Tarbert
(224) 244-0111
gabrielle.tarbert@abbvie.com

Investors:

Liz Shea
(847) 935-2211
liz.shea@abbvie.com

View original content:https://www.prnewswire.com/news-releases/abbvie-to-host-full-year-and-fourth-quarter-2025-earnings-conference-call-302652211.html

SOURCE AbbVie

News Provided by PR Newswire via QuoteMedia

abbvie abbv nyse-abbv pharmaceutical-investing

ABBV

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Demonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac®), supporting potential in patients with inadequate SSRI response

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces the expansion of its investigational compound SVN-015 into the treatment of depression, supported by preclinical data... Keep Reading...

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Demonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac®), supporting potential in patients with inadequate SSRI response

5 Biggest Pharmaceutical ETFs for Investors in 2026

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Provides Update on BayMedica Commercial Business

Invion Advances Global Strategy With New Licencing Agreement

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Latest News

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Interactive Chart

Latest Press Releases

Bunker Hill Announces Final Tranche of Silver Loan Facility

Bunker Hill Announces Final Tranche of Silver Loan Facility

Adoption of Omnibus Incentive Plan & Private Placement Update

Questcorp Mining Provides Clarification on Sharing Arrangement

Related News

Top 5 Canadian Mining Stocks This Week: Vangaurd Mining Gains 141 Percent

Editor's Picks: Gold and Silver Prices Hit New Highs, Then Drop — What's Next?

Lobo Tiggre: Gold, Silver Hit Record Highs, Next "Buy Low" Sector

Ross Beaty: Gold, Silver in "Bubble Territory," What Happens Next?

Is it Time to Take Profits? Experts Share Gold and Silver Strategies in Vancouver

Adoption of Omnibus Incentive Plan & Private Placement Update

Questcorp Mining Provides Clarification on Sharing Arrangement

TOP STOCKS